SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience informs about press release

25 Jan 2025 Evaluate
Supriya Lifescience has informed that the Board of Directors of the Company at their Meeting held on January 24, 2025 has considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2024. The company has attached the Press Release with regard to the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024.

The above information is a part of company’s filings submitted to BSE.

Supriya Lifescience Share Price

636.05 -1.90 (-0.30%)
13-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.00
Cipla 1211.30
Zydus Lifesciences 920.00
Lupin 2316.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×